Skip to main content

Table 1 Demographics and study characteristics in cancer patients receiving external pelvic radiotherapy with or without amifostine prophylaxis.

From: Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis

  Total A* R**
No of patients treated 44 21 23
Gender:    
   Female 23 15 8
   Male 21 5 16
Age:    
   Median (range) 63(34-79) 59 62
Tumor types:    
   Rectal 20 7 13
   Cervical 12 8 4
   Prostate 5 2 3
   Bladder 3 1 3
   Endometrial 2 2 -
   Sarcoma 2 - 2
Mean radiation dose (Gy):   50.4 50.2
  1. *A = Amifostine
  2. **R = Radiotherapy alone